Constarium
← Search

Structure · dataset · 2026

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate Exposure Disrupts the Gut-Liver Axis and Induces Inflammatory-Dominant Hepatotoxicity via Bile Acid-Farnesoid X Receptor Signaling

Listed in ZivaHub

6:2 Chlorinated polyfluoroalkyl ether sulfonate (6:2 Cl-PFESA), as an alternative of perfluorooctanesulfonate (PFOS), has been widely used in the electroplating industry and frequently detected in environmental media.

Description

However, the mechanisms underlying its chronic hepatotoxicity remain incompletely understood, particularly with respect to the gut-liver axis and bile acid homeostasis. To address this knowledge gap, mice were exposed to 6:2 Cl-PFESA via drinking water for 26 weeks, resulting in estimated daily doses of approximately 0.72 and 7.78 μg/kg body weight.

Toxicological evaluation revealed that prolonged 6:2 Cl-PFESA exposure induced hepatic steatosis, oxidative stress, inflammation, and liver dysfunction, accompanied by gut microbiota dysbiosis, colonic inflammation, and elevated lipopolysaccharide (LPS) levels in the colon and liver. Mechanistic analysis indicated that long-term 6:2 Cl-PFESA exposure suppressed hepatic farnesoid X receptor (FXR) signaling, thereby disrupting bile acid homeostasis, inducing gut microbiota dysbiosis, and enhancing lipopolysaccharide translocation, ultimately aggravating liver injury.

Read the rest (1 more)

Notably, pharmacological activation of FXR by obeticholic acid (OCA) partially restored bile acid homeostasis and alleviated hepatotoxicity. Collectively, these findings verify disruption of the gut-liver FXR-bile acid axis as a key mechanism contributing to 6:2 Cl-PFESA-induced liver injury.

Links

Where it is published

Catalogue records · 1

Topics

Provenance · 1 source records, 16 field assertions
SourceKeyLast seenRaw
ZivaHuboai:figshare.com:article/340276668 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[disease].local:disease:cancermapping · zivahub uct ac zavocabulary-mapper@1.0.0keywords['Cancer']
concepts[field].anzsrc:group:3101mapping · zivahub uct ac zavocabulary-mapper@1.0.0keywords['Cell Biology']
concepts[field].anzsrc:group:3103mapping · zivahub uct ac zavocabulary-mapper@1.0.0keywords['Ecology']
concepts[field].anzsrc:group:3105mapping · zivahub uct ac zavocabulary-mapper@1.0.0keywords['Genetics']
concepts[field].anzsrc:group:3107mapping · zivahub uct ac zavocabulary-mapper@1.0.0keywords['Microbiology']
concepts[field].anzsrc:group:3204mapping · zivahub uct ac zavocabulary-mapper@1.0.0keywords['Immunology']
concepts[field].anzsrc:group:3402mapping · zivahub uct ac zavocabulary-mapper@1.0.0keywords['Inorganic Chemistry']
concepts[field].local:field:chemistrymapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:earth-environmentalmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:life-sciencesmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:medicine-healthmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
descriptionsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/description
licensesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/rights
publication_datesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
titlesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/title